The research included a study of the activity of serum β-hydroxybutyrate dehydrogenase (BHBDH) and some biochemical parameters for 147 heart patients (68 myocardial infarction and 79 angina pectoris). The results showed that the group of heart patients who received serum-hydroxybutyrate dehydrogenase increased their activity significantly (224.12 ± 0.82 U/L) compared to the control group (136.73 ± 0.95 U/L). The activity for serum β-hydroxybutyrate dehydrogenase activity for the heart patients group was affected by age and sex, while it was not affected by body mass index and smoking. It also showed a significant increase in levels of haemoglobin, PCV, Glucose, Urea, GPT, GOT, TC, TG, LDL-C, VLDL-C, MPO, LDH, CK-MB with the control group and heart patients group, while showed a significant decrease in levels for ARE, HDL-C. The results showed no significant difference was observed between serum β-hydroxybutyrate dehydrogenase activity in the myocardial infarction group (225.114±1.26 U/L) and angina pectoris group (223.112±1.08U/L), while there was a significant difference in Hb, PCV, Glu, Alb, GOT, GPT, LDH, CK-MB between myocardial infarction patients group and angina pectoris patients group. A linear significant relationship was also found between serum β-hydroxybutyrate dehydrogenase activity with Hb and PCV, while was a linear significant inverse relationship between serum β-hydroxybutyrate dehydrogenase activity with LDL-C, T.C and T.G in the group of heart patients.